AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14524022 — intervention group
Group type: EXPERIMENTAL
Intervention: Discrete plasmapheresis and Fraxiparin
Number of subjects: 394
Study 10566566 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprandial insulin lispro plus sulfonylurea (L + S)
Number of subjects: 423
Study 10566566 — intervention group
Group type: COMPARATOR
Intervention: Bedtime neutral protamine Hagedorn (NPH) insulin plus sulfonylurea (N + S)
Number of subjects: 423
Study 10566566 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprandial insulin lispro plus bedtime NPH insulin (L + N)
Number of subjects: 423
Study 8731070 — intervention group
Group type: EXPERIMENTAL
Intervention: Matching adversity (adversity in the most invested domain according to roles and goals questionnaire)
Number of subjects: 0
Study 8731070 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependency dysfunctional attitudes
Number of subjects: 0
Study 8731070 — intervention group
Group type: EXPERIMENTAL
Intervention: Life events
Number of subjects: 0
Study 8731070 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysfunctional attitudes
Number of subjects: 0
Study 8731070 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological and social factors
Number of subjects: 0
Study 1888402 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG interpretation by Accident & Emergency Senior House Officers
Number of subjects: 279
Study 1888402 — intervention group
Group type: EXPERIMENTAL
Intervention: Management of patients based on ECG interpretation
Number of subjects: 279
Study 6414253 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin administration
Number of subjects: 10
Study 6414253 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol treatment
Number of subjects: 10
Study 6414253 — intervention group
Group type: COMPARATOR
Intervention: Verapamil treatment
Number of subjects: 10
Study 31095006 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate
Number of subjects: 68
Study 31095006 — intervention group
Group type: COMPARATOR
Intervention: Levonorgestrel implant
Number of subjects: 68
Study 31095006 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable plasma HIV
Number of subjects: 68
Study 31095006 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable genital shedding before contraceptive initiation
Number of subjects: 68
Study 31095006 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher plasma efavirenz concentrations
Number of subjects: 68
Study 29097388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with thiazide diuretic and β-blocker
Number of subjects: 314
Study 25245920 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicolumn spinal cord stimulation (SCS)
Number of subjects: 16
Study 24560012 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel, carboplatin, and mapatumumab (10 mg/kg or 30 mg/kg)
Number of subjects: 0
Study 24560012 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin (control arm)
Number of subjects: 0
Study 21184979 — intervention group
Group type: EXPERIMENTAL
Intervention: Live model
Number of subjects: 0
Study 21184979 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote model
Number of subjects: 0
Study 21184979 — intervention group
Group type: COMPARATOR
Intervention: Control group (ate alone)
Number of subjects: 0
Study 20001998 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 117
Study 20001998 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocoumarol
Number of subjects: 117
Study 17479440 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 433
Study 17479440 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 433
Study 15359544 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (1.0% hydrogen peroxide, 0.243% sodium fluoride, sodium tripolyphosphate in a high-cleaning silica base)
Number of subjects: 76
Study 15359544 — intervention group
Group type: COMPARATOR
Intervention: Positive Control Dentifrice (hexametaphosphate-containing whitening dentifrice)
Number of subjects: 76
Study 11606014 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium, low chloride diet (LSD)
Number of subjects: 16
Study 11606014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate diet (NaHCO3)
Number of subjects: 16
Study 11606014 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal sodium chloride diet (NSD)
Number of subjects: 16
Study 11606014 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-EIA subjects)
Number of subjects: 16
Study 10601174 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CrS) - 6 x (5 g Cr‐H(2)O + 5 g dextrose)/day for 5 days
Number of subjects: 14
Study 10601174 — intervention group
Group type: COMPARATOR
Intervention: Placebo - 6 x 5 g dextrose/day for 5 days
Number of subjects: 14
Study 10601174 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (CrS)
Number of subjects: 14
Study 10601174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 8954023 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-677 25 mg/day
Number of subjects: 32
Study 8954023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 1752455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg four times a day for 8 to 16 weeks
Number of subjects: 138
Study 1752455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg twice a day
Number of subjects: 138
Study 1752455 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice a day
Number of subjects: 138
Study 7042087 — intervention group
Group type: EXPERIMENTAL
Intervention: BCVPP (carmustine, cyclophosphamide, vinblastine, procarbazine, and prednisone)
Number of subjects: 0
Study 7042087 — intervention group
Group type: COMPARATOR
Intervention: MOPP (mechlorethamine, vincristine, prednisone, and procarbazine)
Number of subjects: 0
Study 7042087 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (doxorubicin, bleomycin, vinblastine, and DTIC)
Number of subjects: 0
Study 7042087 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0
Study 7042087 — intervention group
Group type: EXPERIMENTAL
Intervention: BCVPP
Number of subjects: 0
Study 7042087 — intervention group
Group type: COMPARATOR
Intervention: MOPP
Number of subjects: 0
Study 7042087 — intervention group
Group type: COMPARATOR
Intervention: Maintenance chemotherapy or BCG immunotherapy
Number of subjects: 0
Study 31013455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis containing THC (Cann‐CBD; 8 mg THC)
Number of subjects: 17
Study 31013455 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis containing THC with CBD (Cann+CBD; 8 mg THC + 10 mg CBD)
Number of subjects: 17
Study 31013455 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo cannabis
Number of subjects: 17
Study 28816578 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Number of subjects: 0
Study 28816578 — intervention group
Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 0
Study 27539273 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprietary glycyrrhizin product
Number of subjects: 12
Study 27539273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (blank control)
Number of subjects: 12
Study 24402598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model for de novo stress urinary incontinence (SUI) after vaginal POP surgery
Number of subjects: 457
Study 24402598 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model
Number of subjects: 457
Study 24402598 — intervention group
Group type: COMPARATOR
Intervention: Colpopexy and Urinary Reduction Efforts trial participants
Number of subjects: 457
Study 21644184 — intervention group
Group type: EXPERIMENTAL
Intervention: High-threat condition messages about potential negative consequences of pandemic flu
Number of subjects: 84
Study 21644184 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping messages describing the rationale and effectiveness of hand washing
Number of subjects: 84
Study 21644184 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not explicitly defined)
Number of subjects: 84
Study 20705784 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthesiologist-led, nurse-based acute pain service group with patient-controlled analgesia
Number of subjects: 423
Study 20705784 — intervention group
Group type: COMPARATOR
Intervention: Control group with IM or IV boluses of opioid analgesia
Number of subjects: 423
Study 18164119 — intervention group
Group type: EXPERIMENTAL
Intervention: Animation-assisted CPR (AA-CPR)
Number of subjects: 85
Study 18164119 — intervention group
Group type: COMPARATOR
Intervention: Dispatcher-assisted CPR (DA-CPR)
Number of subjects: 85
Study 15733805 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-acceptance
Number of subjects: 0
Study 15733805 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning
Number of subjects: 0
Study 15733805 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure
Number of subjects: 0
Study 15733805 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort with caregiving
Number of subjects: 0
Study 12851517 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg/day)
Number of subjects: 328
Study 10541926 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation of front‐crawl arm‐pulling action on a computer‐interfaced isokinetic swim bench
Number of subjects: 12
Study 10541926 — intervention group
Group type: COMPARATOR
Intervention: Arm cranking on a modified cycle ergometer
Number of subjects: 12
Study 8672412 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine serum albumin (BSA)
Number of subjects: 0
Study 8672412 — intervention group
Group type: EXPERIMENTAL
Intervention: Soyabean-protein isolate (< 0.01 g phytic acid/kg)
Number of subjects: 0
Study 8672412 — intervention group
Group type: COMPARATOR
Intervention: Bovine whey, casein, egg albumen
Number of subjects: 0
Study 1458074 — intervention group
Group type: EXPERIMENTAL
Intervention: Yuzpe regimen (ethinyloestradiol 100 micrograms plus levonorgestrel 500 micrograms repeated after 12 hours)
Number of subjects: 616
Study 1458074 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (600 mg repeated after 12 hours)
Number of subjects: 616
Study 1458074 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg single dose)
Number of subjects: 616
Study 6141730 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 9
Study 6141730 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 1%
Number of subjects: 9
Study 6141730 — intervention group
Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 9
Study 29665714 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized intervention for caregivers
Number of subjects: 102
Study 29665714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 102
Study 29079458 — intervention group
Group type: EXPERIMENTAL
Intervention: ANODAL tDCS
Number of subjects: 12
Study 29079458 — intervention group
Group type: COMPARATOR
Intervention: CATHODAL tDCS
Number of subjects: 12
Study 29079458 — intervention group
Group type: COMPARATOR
Intervention: SHAM tDCS
Number of subjects: 12
Study 27149586 — intervention group
Group type: EXPERIMENTAL
Intervention: WalkAide functional electrical stimulation (pulse width, 300 μs; frequency, 33 Hz, 2 hours/d, 3 days/week for 3 months)
Number of subjects: 34
Study 27149586 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy exercise program (3 months)
Number of subjects: 34
Study 27149586 — intervention group
Group type: EXPERIMENTAL
Intervention: WalkAide functional electrical stimulation
Number of subjects: 34
Study 24763370 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch (RS) diet
Number of subjects: 14
Study 24763370 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-starch polysaccharides (NSPs) diet
Number of subjects: 14
Study 24763370 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-loss (WL) diet
Number of subjects: 14
Study 22783048 — intervention group
Group type: EXPERIMENTAL
Intervention: CO₂ insufflation
Number of subjects: 142
Study 22783048 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 142
Study 20213794 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemosensory malingerers
Number of subjects: 88
Study 20213794 — intervention group
Group type: COMPARATOR
Intervention: Nonmalingerers
Number of subjects: 88
Study 19003892 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming
Number of subjects: 45
Study 19003892 — intervention group
Group type: EXPERIMENTAL
Intervention: Golf
Number of subjects: 45
Study 19003892 — intervention group
Group type: COMPARATOR
Intervention: Swimming and Golf
Number of subjects: 45
Study 16471090 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly cisplatin (40 mg/m² per week for six cycles)
Number of subjects: 40
Study 16471090 — intervention group
Group type: COMPARATOR
Intervention: Three-weekly cisplatin (75 mg/m² on days 1, 22, 43, and 64)
Number of subjects: 40
Study 12364842 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 219
Study 12364842 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study 10669911 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg/day of citicoline
Number of subjects: 30
Study 8758141 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (25 mg base/kg over the first 3 days)
Number of subjects: 50
Study 8758141 — intervention group
Group type: COMPARATOR
Intervention: Tetracycline (4 mg/kg four times daily)
Number of subjects: 50
Study 8099637 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 714
Study 8099637 — intervention group
Group type: COMPARATOR
Intervention: Oral poliovirus vaccine (OPV)
Number of subjects: 714
Study 2435150 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy regimen (ABV/ADV) including doxorubicin, vinblastine, bleomycin/actinomycin D, vincristine, dacarbazine.
Number of subjects: 18
Study 2435150 — intervention group
Group type: COMPARATOR
Intervention: Recombinant alpha interferon
Number of subjects: 18
Study 2435150 — intervention group
Group type: COMPARATOR
Intervention: ABV/ADV
Number of subjects: 18
Study 2435150 — intervention group
Group type: COMPARATOR
Intervention: Both treatment arms (recombinant alpha interferon and ABV/ADV)
Number of subjects: 18
Study 30354950 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg intravenous daily)
Number of subjects: 3298
Study 30354950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3298
Study 26535565 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed FIT outreach
Number of subjects: 6000
Study 26535565 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed colonoscopy outreach
Number of subjects: 6000
Study 26535565 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6000
Study 26535565 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy outreach
Number of subjects: 6000
Study 26535565 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT outreach
Number of subjects: 6000
Study 25611729 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard ribavirin dosing (group 1)
Number of subjects: 62
Study 25611729 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and escalating ribavirin dosing (group 2)
Number of subjects: 62
Study 23212700 — intervention group
Group type: EXPERIMENTAL
Intervention: SOD2Val16Ala polymorphism
Number of subjects: 0
Study 23212700 — intervention group
Group type: EXPERIMENTAL
Intervention: GPX1Pro200Leu polymorphism
Number of subjects: 0
Study 23212700 — intervention group
Group type: EXPERIMENTAL
Intervention: CATc.66+78C>T polymorphism
Number of subjects: 0
Study 23212700 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF‐308G>A polymorphism
Number of subjects: 0
Study 23212700 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS positive and general scores
Number of subjects: 0
Study 23212700 — intervention group
Group type: EXPERIMENTAL
Intervention: PANSS positive, negative, and general scores, GAF score
Number of subjects: 0
Study 22226267 — intervention group
Group type: EXPERIMENTAL
Intervention: LGS-on (low glucose suspend feature activated)
Number of subjects: 50
Study 22226267 — intervention group
Group type: COMPARATOR
Intervention: LGS-off (low glucose suspend feature deactivated)
Number of subjects: 50
Study 22226267 — intervention group
Group type: EXPERIMENTAL
Intervention: LGS-on
Number of subjects: 50
Study 22226267 — intervention group
Group type: COMPARATOR
Intervention: LGS-off
Number of subjects: 50
Study 19539437 — intervention group
Group type: COMPARATOR
Intervention: CEW Exposure only
Number of subjects: 40
Study 19539437 — intervention group
Group type: COMPARATOR
Intervention: Exertion only
Number of subjects: 40
Study 19539437 — intervention group
Group type: EXPERIMENTAL
Intervention: Exertion plus CEW Exposure
Number of subjects: 40
Study 19539437 — intervention group
Group type: EXPERIMENTAL
Intervention: Exertion plus additional Exertion
Number of subjects: 40
Study 16423665 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan therapy
Number of subjects: 12
Study 15266029 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-dilution on-line haemofiltration (HF)
Number of subjects: 12
Study 15266029 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis with dialysate temperature 36.5 degrees C (HD(36.5))
Number of subjects: 12
Study 15266029 — intervention group
Group type: COMPARATOR
Intervention: Haemodialysis with dialysate temperature 35.5 degrees C (HD(35.5))
Number of subjects: 12
Study 11371734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Number of subjects: 51
Study 11371734 — intervention group
Group type: COMPARATOR
Intervention: Control (without intraoperative ultrasound)
Number of subjects: 51
Study 10443129 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical levobunolol
Number of subjects: 20
Study 10443129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7719088 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanggan Zhibao (KGZB) oral liquor
Number of subjects: 0
Study 7719088 — intervention group
Group type: COMPARATOR
Intervention: Levamisole (control group)
Number of subjects: 0
Study 2758010 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-fed full-term infants
Number of subjects: 26
Study 2758010 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed full-term infants (unsupplemented)
Number of subjects: 26
Study 2758010 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed preterm infants (unsupplemented)
Number of subjects: 26
Study 2758010 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula-fed full-term infants (supplemented)
Number of subjects: 26
Study 2758010 — intervention group
Group type: COMPARATOR
Intervention: Breast-milk
Number of subjects: 26
Study 2758010 — intervention group
Group type: COMPARATOR
Intervention: Cow's milk formula (unsupplemented)
Number of subjects: 26
Study 5440736 — intervention group
Group type: EXPERIMENTAL
Intervention: 1·2 mega‐units of aqueous procaine penicillin plus 1·0 g of probenecid given orally immediately prior to injection
Number of subjects: 613
Study 5440736 — intervention group
Group type: COMPARATOR
Intervention: 1·2 mega‐units of aqueous procaine penicillin alone
Number of subjects: 613
Study 31699166 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self-report using the Behavior Rating Inventory of Executive Function (BRIEF-A)
Number of subjects: 47
Study 31699166 — intervention group
Group type: COMPARATOR
Intervention: Proxy-report using the Behavior Rating Inventory of Executive Function (BRIEF-A)
Number of subjects: 47
Study 31699166 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Regulation Index scores from BRIEF-A
Number of subjects: 47
Study 31699166 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognition Index scores from BRIEF-A
Number of subjects: 47
Study 31699166 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance-based measures of executive functioning
Number of subjects: 47
Study 30074459 — intervention group
Group type: EXPERIMENTAL
Intervention: No midline shift
Number of subjects: 892
Study 30074459 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-5 mm midline shift
Number of subjects: 892
Study 30074459 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-10 mm midline shift
Number of subjects: 892
Study 30074459 — intervention group
Group type: EXPERIMENTAL
Intervention: > 10 mm midline shift
Number of subjects: 892
Study 27163895 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine 150 mg once daily for 8 weeks
Number of subjects: 0
Study 27163895 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily for 8 weeks
Number of subjects: 0
Study 24169068 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich meal
Number of subjects: 10
Study 24169068 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich meal
Number of subjects: 10
Study 24169068 — intervention group
Group type: COMPARATOR
Intervention: Fasting state
Number of subjects: 10
Study 22499405 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month exercise program
Number of subjects: 20
Study 22499405 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 20
Study 21181361 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition-Motivation-Emotional Intelligence-Resistance Skills (CMER) program
Number of subjects: 798
Study 18071720 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and irinotecan with concurrent radiation (50.4 Gy)
Number of subjects: 59
Study 18071720 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine, irinotecan and cetuximab with concurrent radiation (50.4 Gy)
Number of subjects: 59
Study 15772214 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus eluting stent
Number of subjects: 238
Study 15772214 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent
Number of subjects: 238
Study 15259471 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole therapy
Number of subjects: 72
Study 15259471 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 10562782 — intervention group
Group type: EXPERIMENTAL
Intervention: melatonin 5 mg
Number of subjects: 75
Study 10562782 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 15 mg
Number of subjects: 75